PBAC's latest decision on Ondansetron: Recommended with restriction (2020). Considered for Nausea and vomiting associated with radiotherapy or oral chemotherapy being used to treat malignancy.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2020
Submissions
1
2020 → 2020
Eligible population
Patients receiving oral chemotherapy to treat malignancy experiencing nausea and vomiting.
Therapy area
Oncology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Economic model
Cost-minimisation
ICER note
Not modelled. This is a minor submission (expansion of existing indication) with no formal economic evaluation; PBAC noted cost-effectiveness based on significant price reductions since first listing.